Osteoporosis Testing, Pharmaceutical and Nutraceutical Management

More than 53 million Americans either have osteoporosis or at high risk due to low bone mass, nearly 40% of women over 50 years old will suffer an osteoporosis fracture and debilitating acute and chronic pain in the elderly is often attributed to fragility fractures and can lead to further disability and early morality. Despite how common and deadly osteoporosis is, there is confusion about the clinical utility of diagnostic and screening technologies and laboratory tests for their ability to predict fractures and provide crucial information for treatment and monitoring of fracture risk. There’s also limited understanding about the growing list of medications that impact bone metabolism, decrease bone mineral density (BMD), and increase fractures.

This webinar evaluates currently available diagnostic and screening technologies and the most common laboratory tests for their ability to predict fractures and provide crucial information for treatment and monitoring of fracture risk. It also evaluates the damaging skeletal effects of some of the most commonly prescribed medications, the ability for osteoporosis medications to prevent fragility fractures and provides clinicians with recommended tests for patients at risk of bone loss.

The webinar recording lasts 82 minutes, including a Q & A session.